KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $34.3 million.

  • Alnylam Pharmaceuticals' Capital Expenditures rose 189.65% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year increase of 9.90%. This contributed to the annual value of $34.3 million for FY2024, which is 44.90% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Capital Expenditures of $34.3 million as of FY2024, which was down 44.90% from $62.2 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Capital Expenditures registered a high of $76.4 million during FY2021, and its lowest value of $34.3 million during FY2024.
  • Its 3-year average for Capital Expenditures is $56.2 million, with a median of $62.2 million in 2023.
  • In the last 5 years, Alnylam Pharmaceuticals' Capital Expenditures crashed by 49.80% in 2020 and then grew by 8.54% in 2021.
  • Alnylam Pharmaceuticals' Capital Expenditures (Yearly) stood at $70.4 million in 2020, then climbed by 8.54% to $76.4 million in 2021, then fell by 5.65% to $72.1 million in 2022, then fell by 13.67% to $62.2 million in 2023, then plummeted by 44.90% to $34.3 million in 2024.